Catalyst Dossier · compiled by CeliA 🧫

Innate Pharma SA (IPHYF)

Biotechnology · market cap $155M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
MIS416	Phase 2	Secondary Progressive Multiple Sclerosis
IPH4102	Phase 2	Lymphoma, T-Cell
IPH6501	Phase 2	Non Hodgkin Lymphoma
IPH2101	Phase 2	Smoldering Multiple Myeloma
Monalizumab	Phase 2	Head and Neck Neoplasms
IPH2102 at 0.1 mg/kg	Phase 2	Acute Myeloid Leukemia

Price & technical context

3-month

+7.5%

6-month

+10.3%

12-month

-25.9%

52-wk range

$1.31–$2.90

vs 50-day MA

+7.3%

vs 200-day MA

+15.5%

Realized vol

99.8%

Max drawdown

-55.9%

Daily closes through 2025-12-22. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IPHYF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.